$BOLD

TANG KEVIN purchased $715K of BOLD (indirect holdings)

TANG KEVIN purchased 286,333 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.50 ($2.47–$2.56, $0.71M total) across 6 trades over 2026-06-25 to 2026-06-29.

Original reporting
SEC EDGAR · TANG KEVIN
Published Jun 29, 2026, 11:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BOLD
Bullish
medium confidence
Mentioned
$BOLD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDBullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase by a 10% owner totaling ~$714.8K across six trades, with holdings after the transaction at 2,533,845 shares.

02

Market read

Traders may treat the filing as a modest sentiment input, but it does not introduce new operational or financial guidance.

03

What to watch

The purchase price range ($2.47–$2.56) may reflect prevailing liquidity/market conditions; without context on prior holdings or motivations, the signal strength is uncertain.

Relevance 6/10Novelty 6/10Timing: filed after-hours 2026-06-29 for trades dated 2026-06-25 to 2026-06-29

Background

The article is an SEC Form 4 insider transaction disclosure for Boundless Bio, Inc. (BOLD).

Company-level read

Ticker impact

$BOLDBullishMedium confidence
Context

SEC Form 4 shows 10% owner Tang Kevin bought 286,333 shares of Boundless Bio (BOLD) for ~$714.8K at $2.47–$2.56.

Expected impact

Near-term impact likely limited; any effect is sentiment-driven and may fade unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped (filed 2026-06-29), but it lacks new company fundamentals (no guidance, trial, or deal) and is an indirect holding purchase.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical signal.

None indicated.

None indicated.

Counterpoint

Insider buying can be routine (tax/portfolio rebalancing) and the indirect nature plus lack of a 10b5-1 plan reduces interpretability.

Key entities

  • Boundless Bio, Inc.

    Public company subject of the Form 4 insider transaction disclosure.

  • Tang Kevin

    10% owner reporting an open-market purchase via indirect holdings.

Related articles